{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T19:45:42Z","timestamp":1768765542147,"version":"3.49.0"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T00:00:00Z","timestamp":1342483200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>In this study, we explored the possible relationships between plasma fluvoxamine levels and clinical features and\/or response in adult obsessive\u2013compulsive disorder (OCD) patients treated with this drug for 6\u2009months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty OCD outpatients of both sexes who were already taking fluvoxamine (mean dose\u2009\u00b1\u2009SD: 216.7 \u00b186.2) for at least 4\u2009weeks were included in the study. The severity of OCD was assessed by means of the Yale\u2013Brown obsessive\u2013compulsive scale (Y\u2010BOCS). The fluvoxamine plasma levels were measured by high\u2010performance liquid chromatography analysis. All evaluations were performed after 4\u2009weeks (t1) and 6\u2009months (t2) of fluvoxamine intake.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The plasma levels of fluvoxamine remained stable at the two assessment times, with no sex\u2010related differences. Sixteen (80%) patients responded to treatment as shown by the significant (&gt;35%) decrease of the Y\u2010BOCS total score. Men's compulsions improved more than those of women. Significant and positive correlations were detected between fluvoxamine plasma levels at t1 and t2 and the difference (delta) of the Y\u2010BOCS total and compulsion subscale scores between t1 and t2. Another significant, albeit negative, correlation was measured between the difference of the compulsion subscale score and the difference of fluvoxamine levels at t1 and t2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These findings underline the potential importance of evaluating fluvoxamine plasma levels in OCD and their relationships with the clinical response that may be gender\u2010related on specific symptoms. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2240","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T04:25:43Z","timestamp":1342671943000},"page":"397-402","source":"Crossref","is-referenced-by-count":9,"title":["Plasma fluvoxamine levels and OCD symptoms\/response in adult patients"],"prefix":"10.1002","volume":"27","author":[{"given":"Donatella","family":"Marazziti","sequence":"first","affiliation":[{"name":"Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Baroni","sequence":"additional","affiliation":[{"name":"Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gino","family":"Giannaccini","sequence":"additional","affiliation":[{"name":"Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Piccinni","sequence":"additional","affiliation":[{"name":"Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Picchetti","sequence":"additional","affiliation":[{"name":"Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Massimetti","sequence":"additional","affiliation":[{"name":"Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Schiavi","sequence":"additional","affiliation":[{"name":"Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionella","family":"Palego","sequence":"additional","affiliation":[{"name":"Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Catena\u2010Dell'Osso","sequence":"additional","affiliation":[{"name":"Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200206000-00012"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-011-2293-5"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900026924"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.3.5.741"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.31887\/DCNS.2005.7.3\/pbaumann","article-title":"Arbeitsgemeinschaft fur neuropsychopharmakologie und pharmakopsyhiatrie \u2013 therapeutic drug monitoring group. The AGNP\u2010TDM expert group consensus guidelines: focus on therapeutic monitoring of antidepressants","volume":"7","author":"Baumann P","year":"2005","journal-title":"Dialogues Clin Neurosci"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199609000-00004"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1077(200008)15:6<453::AID-HUP228>3.0.CO;2-F"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(93)90030-K"},{"issue":"20","key":"e_1_2_6_11_1","first-page":"85","article-title":"Differential pharmacology of newer antidepressants","volume":"59","author":"DeVane CL","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145704004675"},{"key":"e_1_2_6_13_1","volume-title":"Structured Clinical Interview for DSM\u2010IV Axis I Disorders\u2010Patient Edition (SCID\u2010I P, Version 2.0, 4 97 revision)","author":"First MB","year":"1997"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810010038006"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110054008"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110048007"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199603000-00003"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199500291-00003"},{"issue":"10","key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/clinchem\/38.10.2082","article-title":"Automated determination of fluvoxamine in plasma by column\u2010switching high\u2010performance liquid chromatography","volume":"38","author":"H\u00e4rtter S","year":"1992","journal-title":"Clin Chem"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-007-1005-y"},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1192\/S0007125000297924","article-title":"Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study","volume":"35","author":"Hohagen F","year":"1998","journal-title":"Br J Psychiatry Suppl"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0604"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/08039489309104119"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.04390010015002"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(93)90290-3"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00212778"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199200432-00003"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/10401239209150443"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903446948"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986710793176384"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32834cde39"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199008000-00005"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199705000-00002"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301199"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.317"},{"key":"e_1_2_6_37_1","first-page":"301","article-title":"Management of obsessive\u2010compulsive disorder with fluvoxamine extended release","volume":"5","author":"Ordacgi L","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03188757"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2008.44.12.1299291"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200004000-00009"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145702002900"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199408000-00002"},{"key":"e_1_2_6_43_1","first-page":"23","article-title":"Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness","volume":"52","author":"Preskorn SH","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0214"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1024\/0369-8394.95.17.671"},{"key":"e_1_2_6_46_1","first-page":"97","article-title":"A preliminary report on clinical response and plasma levels of clomipramine and desmethylclomipramine in obsessive\u2010compulsive neurosis","volume":"53","author":"Stern RS","year":"1977","journal-title":"Postgrad Med J"},{"key":"e_1_2_6_47_1","first-page":"516","article-title":"19F magnetic resonance spectroscopy investigation in vivo of acute and steady state brain fluvoxamine levels in obsessive\u2010compulsive disorder","volume":"14","author":"Strauss WL","year":"1997","journal-title":"Am J Psychiatry"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n1209"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02657069"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014468"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1130080605"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2240","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:42:49Z","timestamp":1700599369000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1002\/hup.2240"],"URL":"https:\/\/doi.org\/10.1002\/hup.2240","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}